Core Scientific, Inc. (CORZ) Moves 33.0% Higher: Will This Strength Last?
Core Scientific, Inc. (CORZ) shares soared 33% in the last trading session to close at $16.36. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 14.1% gain over the past four weeks.
The recent surge in Core Scientific shares can be attributed to renewed buyout talks with CoreWeave, an AI cloud infrastructure provider. According to reports, CoreWeave has re-entered advanced negotiations to acquire Core Scientific, reigniting investor excitement just months after its initial offer was rejected. This time, with Core Scientific's market cap now exceeding $3.7 billion, the expected deal could come at a much higher premium. Investors are optimistic that a potential acquisition would unlock significant value, especially given Core Scientific's pivotal role in AI infrastructure and high-performance computing.
This company is expected to post quarterly loss of $0.07 per share in its upcoming report, which represents a year-over-year change of -75%. Revenues are expected to be $83.33 million, down 41% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Core Scientific, Inc., the consensus EPS estimate for the quarter has been revised 2.6% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on CORZ going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Core Scientific, Inc. belongs to the Zacks Financial - Miscellaneous Services industry. Another stock from the same industry, PJT Partners (PJT), closed the last trading session 2.5% higher at $166.36. Over the past month, PJT has returned 7.5%.
For PJT Partners, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $1.11. This represents a change of -6.7% from what the company reported a year ago. PJT Partners currently has a Zacks Rank of #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Core Scientific, Inc. (CORZ) : Free Stock Analysis Report
PJT Partners Inc. (PJT) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
LGI Homes Introduces Medley Park in Clayton, NC: A Stylish Townhome Community Close to Raleigh
CLAYTON, N.C., June 27, 2025 (GLOBE NEWSWIRE) — LGI Homes (NASDAQ: LGIH) is excited to unveil Medley Park, a vibrant new townhome community located in the heart of downtown Clayton, just a 30‑minute drive from Raleigh, North Carolina. Designed for families and first-time buyers, Medley Park introduces the 'Dagny' floor plan, a thoughtfully crafted three‑bedroom, two-and-a-half‑bath townhome spanning 1,231 square feet. The Dagny townhome presents modern, open‑concept living highlighted by a chef‑inspired kitchen with stunning granite countertops, stainless steel appliances, and designer wood cabinetry. Upstairs, you'll enjoy a spacious master suite complete with a walk‑in closet, two additional bedrooms, a full bath, and the convenience of a second‑floor laundry room. Exterior options enhance curb appeal and personalization, from stone‑accent facades to plank‑style siding, varied color palettes and trim, and even a front porch or stoop configuration, all contributing to a custom streetscape presence. The Dagny will start from $284,900. At Medley Park, LGI Homes brings quality finishes and energy-efficient design to every residence. Buyers will appreciate premium features included at no extra cost, such as granite countertops, energy-saving appliances, designer plumbing fixtures, crown-molding cabinets, and recessed LED lighting, reflecting the builder's dedication to delivering turnkey homes. Conveniently situated within walking distance of Clayton's downtown shops and restaurants, Medley Park also offers immediate access to green spaces and recreation, including the newly-opened Clayton Municipal Park, and easy commuting to employment hubs in Raleigh. Medley Park will open for sales on Saturday, June 28, with exclusive savings available for one weekend only. Prospective homeowners are invited to call (855) 687-8221 ext. 500 to request a VIP tour, or visit the sales office at 193 Seville Way, Clayton, NC 27520, open daily from 11 a.m. to 7 p.m. About LGI Homes Headquartered in The Woodlands, Texas, LGI Homes, Inc. is a pioneer in the homebuilding industry, successfully applying an innovative and systematic approach to the design, construction and sale of homes across 36 markets in 21 states. As one of America's fastest growing companies, LGI Homes has closed over 75,000 homes since its founding in 2003 and has delivered profitable financial results every year. Nationally recognized for its quality construction and exceptional customer service, LGI Homes was named to Newsweek's list of the World's Most Trustworthy Companies. LGI Homes' commitment to excellence extends to its more than 1,000 employees, earning the Company numerous workplace awards at the local, state and national level, including the Top Workplaces USA 2025 Award. For more information about LGI Homes and its unique operating model focused on making the dream of homeownership a reality for families across the nation, please visit the Company's website at MEDIA CONTACT: Rachel Eaton (281) 362-8998 ext. 2560 A photo accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
2 hours ago
- Business Upturn
Pliant Therapeutics Provides Update on BEACON-IPF
Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis (IPF). BEACON-IPF Trial Update BEACON-IPF was a randomized, double-blind, placebo-controlled, global Phase 2b/3 clinical trial evaluating patients with IPF. In March of this year, Pliant announced the voluntary discontinuation of BEACON-IPF following a prespecified data review and recommendation by the trial's independent Data Safety Monitoring Board (DSMB), as well as a secondary review and recommendation by an outside expert panel, citing an imbalance in IPF-related adverse events. Following an analysis of the full safety and efficacy data from the BEACON-IPF trial, the Company is discontinuing development of bexotegrast in IPF. Results showed that at doses of 160 mg and 320 mg, bexotegrast demonstrated an unfavorable risk-benefit profile. Compared to placebo, bexotegrast-treated participants showed an increased risk of experiencing adverse events associated with IPF disease progression, defined as events of worsening of IPF and acute IPF exacerbation, respiratory-related hospitalization, and/or all-cause mortality. The average time to disease progression for bexotegrast-treated participants was 33 weeks, suggesting that the safety risk may not be apparent with shorter dosing duration as was the case in the prior INTEGRIS-IPF Phase 2a trial. At Week 12, bexotegrast 160 mg and 320 mg treatment groups demonstrated improvements in forced vital capacity (FVC) decline of 72 mL (p<0.05) and 46 mL (p>0.05), respectively, compared to placebo. At Week 24, bexotegrast 160 mg and 320 mg treatment groups demonstrated improvements in FVC decline of 58 mL (p>0.05) and 8 mL (p>0.05), respectively, compared to placebo. The full results from BEACON-IPF will be submitted for future publication. 'Although the decision to discontinue bexotegrast in IPF is disappointing for us and the many patients in need of new treatment options, we believe it is the right decision to protect patient safety,' said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. 'We sincerely thank all patients, their caregivers, the study investigators and their research teams who were part of the BEACON-IPF clinical program for their extensive efforts.' Oncology Phase 1 Enrollment Continues PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, designed to block TGF-β activation in the tumor microenvironment. PLN-101095 is currently undergoing a Phase 1 open-label trial as monotherapy and in combination with pembrolizumab in patients with solid tumors that are resistant to immune checkpoint inhibitors. In March, the Company announced interim results from this trial showing that PLN-101095 was generally well tolerated with confirmed partial responses in 50% of patients at highest dose tested to date, across multiple tumor types. The trial is currently enrolling the fifth of five planned dose cohorts. Early Programs Supported by Proprietary Platform The Company's drug discovery platform consists of a proprietary library of over 15,000 integrin binding molecules, a comprehensive screening assay system (binding, integrin confirmation, ligand-induced internalization) and an advanced live human tissue program. The Company believes in the broad applicability of the platform across multiple disease areas including delivery of drug payloads to cells utilizing integrin receptor-binding molecules as tissue-specific delivery and internalization mechanisms. About Pliant Therapeutics, Inc. Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of integrin-based therapeutics. Pliant is conducting a Phase 1 study for PLN-101095, a small molecule, dual-selective inhibitor of α v ß 8 and α v ß 1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α 7 β 1 targeting muscular dystrophies. Pliant's early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules. For additional information, please visit: Follow us on social media X, LinkedIn and Facebook. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'may,' 'will,' 'expect,' 'anticipate,' 'estimate,' 'intend,' and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those regarding development plans for PLN-101095, PLN-101325 and the Company's proprietary platform; and the Company's efforts to align its workforce and operations for its next steps. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Pliant Therapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those related to the development and commercialization of our product candidates, including any delays in our ongoing or planned preclinical or clinical trials, the impact of current macroeconomic, geopolitical and marketplace conditions on our business, operations, clinical supply and plans, our reliance on single-source third parties located in foreign jurisdictions, including China, for critical aspects of our development operations, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, including the availability of additional term loans under our loan facility, and our ability to obtain and maintain intellectual property protection for our product candidates. These and additional risks are discussed in the sections titled 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in our Quarterly Report on Form 10-Q for the period ended March 31, 2025 which are available on the SEC's website at Unless otherwise noted, Pliant is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. Investor and Media Contact: Christopher KeenanVice President, Investor Relations and Corporate CommunicationsPliant Therapeutics, Inc. [email protected]
Business Wire
2 hours ago
- Business Wire
Informa TechTarget to Announce 2025 First Quarter Financial Results on July 1, 2025
NEWTON, Mass.--(BUSINESS WIRE)--TechTarget, Inc. (Nasdaq: TTGT) ('Informa TechTarget' or the 'Company'), a leading growth accelerator for the B2B Technology sector, today announced that it plans to release its Q1 2025 financial results for the three months ended March 31, 2025 after the market closes on Tuesday, July 1, 2025. The Company's Chief Executive Officer, Gary Nugent, and Chief Financial Officer, Dan Noreck, will host a live conference call and webcast at 5:00 p.m. Eastern Time on that day to discuss the Company's financial results and outlook. The Q1 2025 financial results will be available prior to the conference call and webcast on the investor relations section of the Company's website at Conference Call Dial-In Information: United States (Toll Free): 1-833-470-1428 United States: 1-404-975-4839 United Kingdom (Toll Free): +44 808 189 6484 United Kingdom: +44 20 8068 2558 Global Dial-in Numbers Access code: 557186 Please access the call at least 10 minutes prior to the time the conference is set to begin. Please ask to be joined into the Informa TechTarget call. Conference Call Webcast Information: This webcast can be accessed via Informa TechTarget's website at Conference Call Replay Information: A replay of the conference call will be available via telephone beginning one (1) hour after the conference call through July 31, 2025 at 11:59 p.m. ET. To hear the replay: United States (Toll Free): 1-866-813-9403 United States: 1-929-458-6194 Access Code: 670569 A web version will also be available for replay during the same period on Informa TechTarget's website at About Informa TechTarget TechTarget, Inc. (Nasdaq: TTGT), which also refers to itself as Informa TechTarget, informs, influences and connects the world's technology buyers and sellers, helping accelerate growth from R&D to ROI. With a vast reach of over 220 highly targeted technology-specific websites and over 50 million permissioned first-party audience members, Informa TechTarget has a unique understanding of and insight into the technology market. Underpinned by those audiences and their data, we offer expert-led, data-driven, and digitally enabled services that have the potential to deliver significant impact and measurable outcomes to our clients: Trusted information that shapes the industry and informs investment Intelligence and advice that guides and influences strategy Advertising that grows reputation and establishes thought leadership Custom content that engages and prompts action Intent and demand generation that more precisely targets and converts Informa TechTarget is headquartered in Boston, MA and has offices in 19 global locations. For more information, visit and follow us on LinkedIn. © 2025 TechTarget, Inc. All rights reserved. All trademarks are the property of their respective owners.
